Osteoporosis International

, Volume 19, Issue 6, pp 819–827

The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden

  • N. Zethraeus
  • O. Ström
  • F. Borgström
  • J. A. Kanis
  • B. Jönsson
Original Article

DOI: 10.1007/s00198-007-0511-0

Cite this article as:
Zethraeus, N., Ström, O., Borgström, F. et al. Osteoporos Int (2008) 19: 819. doi:10.1007/s00198-007-0511-0

Abstract

Summary

This paper assessed the cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden, using one model and a societal perspective. Cost-effective scenarios were found in all these chronic disorders. These findings are of relevance for decisions on the efficient allocation of health care resources.

Introduction

There is a need to assess the cost-effectiveness (CE) of treatment of osteoporosis from a societal perspective and to relate this to the CE of interventions in other disease areas. This is of relevance for decisions on the efficient allocation of health care resources within and between disease areas. The purpose of the paper was to estimate the CE of the treatment and prevention of osteoporosis and to put that into the perspective of treating hypertension and hyperlipidaemia. The CE was assessed for different high risk female populations aged 50–80 years.

Methods

The estimation of CE was based on a model populated with data for Sweden.

Results

Compared to no intervention, a 5-year treatment of osteoporosis, hypertension, and hyperlipidaemia, is cost effective for most of the assessed high risk female populations. The cost per gained quality adjusted life year (QALY) for the treatment of a 70-year-old woman never exceeded SEK 330,000 (US$ 44,000), which is generally judged as an acceptable cost for a gained QALY.

Conclusions

The study demonstrates that it is possible to produce reliable estimates of the CE of treatments in different disease areas within the context of a single model.

Keywords

Bisphosphonates Cost Hydrochlorthiazides QALY Statins 

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2007

Authors and Affiliations

  • N. Zethraeus
    • 1
  • O. Ström
    • 2
  • F. Borgström
    • 2
    • 3
  • J. A. Kanis
    • 4
  • B. Jönsson
    • 1
  1. 1.Centre for Health EconomicsStockholm School of EconomicsStockholmSweden
  2. 2.European Health EconomicsStockholmSweden
  3. 3.Medical Management Centre at the Karolinska Institutet (KI)StockholmSweden
  4. 4.Centre for Metabolic Bone Diseases (WHO Collaborating Centre)University of Sheffield Medical School, UKSheffieldUK

Personalised recommendations